In order to optimize therapy, a full understanding of the pharmacokinetics of any systemic therapy is desired. We routinely model the pharmacokinetic data of agents being tested for antitumor activity and correlate that with activity and/or toxicity (pharmacodynamics modeling). The laboratory is currently collaborating on 60 clinical trials to characterize the clinical pharmacology of novel chemotherapy agents. Analysis of pharmacokinetic data (using concentration measurements provided by sample analysis using validated assays) allows for assessment of drug disposition, including the absorption, distribution, metabolism and excretion of a drug. Modeling this data, essentially describing these physiological processes as a mathematical equation, allows for optimization of drug administration (including dose and frequency of dosing,) in silico. Pharmacokinetics have been completed for the histone deacetylase inhibitor MS-275, in a clinical trial which investigated the effects of food on drug disposition. Fasting prior to and immediately after MS-275 was administered orally, on a once-weekly schedule, was found to result in decreased interindividual variability in drug exposure. Population pharmacokinetic modeling of Depsipeptide (FK228) using data from multiple CCR clinical trials determined that common polymorphisms in the ABCB1, CYP3A4 and CYP3A5 genes do not appreciably influence the pharmacokinetics of FK228. Furthermore, age, renal function, and body size and composition are anticipated to have little or no impact on the systemic exposure to FK228. The developed population pharmacokinetic model was validated and can be used for the future clinical trials simulation and prediction. Population pharmacokinetic modeling of midazolam, often administered as a probe drug for assessing CYP3A activity, is currently ongoing. For example, midazolam PK is being studied as a CYP3A4 Probe for nelfinavir pharmacokinetics. This study assessed the correlation of nelfinavir PK with CYP3A4 activity measured by midazolam clearance. Preliminary data show that midazolam demonstrated different PK depending on the presence or absence of nelfinavir. A significant decrease in midazolam clearance was observed on day 20, as compared to pre-nelfinavir (P=0.0009), based on pairwise analysis. The decline in midazolam clearance suggests CYP3A4 inhibition by nelfinavir. However, midazolam clearance did not significantly correlate with nelfinavir clearance after first dose or at steady-state. Nelfinavir is known to be metabolized by several CYP450 enzymes, including the CYP3A isozymes. Based on the significant decline in midazolam clearance, yet little effect on nelfinavir pharmacokinetics, it appears unlikely that potential autoinhibition of CYP3A is significantly impacting the pharmacokinetics of nelfinavir. As such, one cannot predict nelfinavir PK using midazolam as a phenotyping probe. However, the significant decrease in midazolam clearance does highlight the possibility of nelfinavir increasing the toxicity (through increase exposure/decreased clearance) of other CYP3A4 substrates that may be administered concurrently. We recently completed a clinical study of ABI-007 (Abraxane), an albumin-bound nanoparticle formulation of paclitaxel, devoid of any additional excipients. We hypothesized that this change in formulation alters the systemic disposition of paclitaxel compared with conventional solvent-based formulations (Taxol), and leads to improved tolerability of the drug. Patients with malignant solid tumors were randomized to receive the recommended single agent dose of ABI-007 (260 mg/m2 as a 30 minute infusion) or Taxol (175 mg/m2 as a 3 hour infusion). Following cycle 1, patients crossed over to the alternate treatment. Pharmacokinetic studies were carried out for the first cycle of Taxol and the first two cycles of ABI-007. Seventeen patients were treated, with 14 receiving at least one cycle each of ABI-007 and Taxol. No change in ABI-007 pharmacokinetics was found between the first and second cycles, suggesting limited intrasubject variability. Total drug exposure was comparable between the two formulations (P= 0.55) despite the dose difference. However, exposure to unbound paclitaxel was significantly higher following ABI-007 administration, due to the increased free fraction (0.063 0.021 vs 0.024 0.009, P less than 0.001). This study demonstrates that paclitaxel disposition is subject to considerable variability depending on the formulation used. Since systemic exposure to unbound paclitaxel is likely a driving force behind tumoral uptake, these findings explain, at least in part, previous observations that the administration of ABI-007 is associated with augmented antitumor efficacy as compared with Taxol. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Romidepsin is a potent histone deacetylase inhibitor under clinical development. The objective of this study was to evaluate the effect of demographic, clinical, and pharmacogenetic covariates on the pharmacokinetics of romidepsin in patients with T-cell lymphoma. Pharmacokinetic assessment was done in 98 patients enrolled in a phase II study who received 14 or 18 mg/m2 of romidepsin as a 4-hour infusion on day 1 during their first treatment cycle. Population modeling was done using a nonlinear mixed effects modeling approach to explore the effects of polymorphic variations in CYP3A4, CYP3A5, SLCO1B3, and ABCB1, all of which encode genes thought to be involved in romidepsin disposition. A two-compartment model with linear kinetics adequately described the romidepsin disposition. Population clearance was 15.9 L/h with between-patient variability of 37%. ABCB1 2677G greater than T/A variant alleles tended toward a reduced clearance and lower volume of tissue distribution, but this was not supported by a statistical significance. Genetic variations in CYP3A4/5 and SCLO1B3 had no effect on the systemic exposure. The population pharmacokinetic analysis indicates moderate interindividual variability in romidepsin pharmacokinetics and no clinically relevant covariates associated with the unexplained pharmacokinetic variability of romidepsin in this population. Studies are currently underway to determine the pharmacokinetic comparative analysis of flavopiridol co-Administered with bortezomib via two dosing schemes.
Showing the most recent 10 out of 27 publications
